Novonesis Outlines Ambitious Long-Term Strategy Towards 2030
Novonesis has recently shared a comprehensive update about its long-term growth strategy, known as the ‘GROW’ strategy, aiming for significant advancements by 2030. The focus will be on enhancing core business operations, alongside making substantial reinvestments to ensure sustained future growth. This strategy is positioned to drive a compound annual growth rate (CAGR) of organic sales between 6-9%, an adjusted EBITDA margin estimated at roughly 39%, and an adjusted Return on Invested Capital (ROIC) excluding goodwill of around 16%.
Driving Performance in Biosolutions
As an industry leader, Novonesis is strategically placed to propel robust growth in the biosolutions market. The company's diversified presence across various sectors enables it to provide customized, value-driven solutions that resonate with diverse customer needs. The foundation of Novonesis's success lies in three key areas: a profound understanding of their customers, unmatched innovation capabilities, and a high-level operational efficiency that allows them to effectively scale and deliver cost-effective biosolutions. Given global challenges such as population growth, rising energy demands, health and nutrition advancements, and environmental concerns, the demand for innovative biosolutions is expected to soar.
Insights from Leadership
Ester Baiget, the President & CEO of Novonesis, expressed her confidence in achieving the firm's previously established targets for 2025, noting that the biosolutions sector shows tremendous potential. Baiget stated, "We are clearly on track to deliver on our 2025 targets that were set when we announced the combination. The potential for biosolutions continues to be strong, and Novonesis is uniquely positioned to achieve accelerated profitable growth towards 2030 and beyond. The more we grow, the more long-term value and impact we create for shareholders, customers, and the planet."
Growth Opportunities and Strategic Focus Areas
Novonesis has crafted a well-balanced growth matrix that blends increases in market volumes with strategic pricing strategies, upselling, and market penetration. The company remains committed to exploring and tapping into avenues with substantial long-term growth potential. Current focus areas for exploration include Biopharma Processing Aids, Future Fuels and Chemicals, as well as Specialized Nutrition Proteins.
Key Financial Targets
The ambitious targets set for the year 2030 highlight various growth expectations:
- Organic sales projected to achieve a CAGR of 6-9%, primarily fueled by increased volume complemented by annual price contributions of 1-2%. Both the Food & Health and Planetary Health Biosolutions divisions are expected to thrive, with emerging markets anticipated to outpace their developed counterparts.
- An adjusted EBITDA margin targeted at approximately 39% by 2030, assuming current currency rates. The strategic period will encompass synergies along with impactful investments in innovation, marketing, and commercialization to propel growth both in the short and long run.
- The anticipated adjusted ROIC excluding goodwill is around 16% by 2030, a significant increase from a pro forma 8.3% expected in 2024.
- A reaffirmation of non-financial ambitions, coupled with investments to achieve these goals.
Strategic Investments and Development Plans
As part of the 2030 agenda, Novonesis plans to execute elevated capital expenditure as a percentage of sales in its early strategy phases to bolster enduring high-growth momentum. Investments will also encompass the deployment of a new ERP system and initiatives aimed at enhancing sustainability practices. The company is focusing on global investment to meet rising demand while creating operational flexibility across regions. Over time, the capital expenditure percentage is expected to taper down to high-single digits as a portion of sales by the strategy's conclusion.
Capital Allocation Strategy
Novonesis's capital allocation framework is designed to maintain a net debt/EBITDA ratio of around 1.5x, in line with its strategic policies. Furthermore, the company aims for a dividend payout ratio ranging between 40% to 60% of adjusted net profit, providing an attractive return for shareholders.
Looking Ahead to 2030
Details on the 2030 strategy will be further disclosed during a conference call associated with the extended H1 2025 report. This call is set to take place at 09:00 CET. Preparatory materials will be shared shortly before the event.
Frequently Asked Questions
What is the main goal of Novonesis's GROW strategy?
The GROW strategy aims to enhance organic sales growth, improve profit margins, and increase ROIC by 2030.
How is Novonesis positioned in the biosolutions market?
Novonesis has a competitive edge through strong customer understanding, innovative capabilities, and efficiency in production and scaling biosolutions.
What are the expected financial targets for 2030?
Novonesis projects a 6-9% organic sales CAGR, an adjusted EBITDA margin of around 39%, and a ROIC of approximately 16% excluding goodwill.
Are there specific areas of focus for future growth?
Yes, Novonesis is focusing on Biopharma Processing Aids, Future Fuels and Chemicals, and Specialized Nutrition Proteins to drive future growth.
What is the company's approach towards capital expenditure?
Novonesis plans to elevate capital expenditure initially but aims to reduce it to high-single digits as a percentage of sales towards the end of the strategy period.
